Our study demonstrates that these features extend to the immunotherapy setting, where the presence of SPP1+BCL2A1+ TAMs is highly associated with increased Treg responses and impaired T-cell responses, particularly in non-responders to ICB therapy in HCC patients. Here, SPP1 is linked to hepatocellular carcinoma.